754 related articles for article (PubMed ID: 30658727)
1. Microbiome as a therapeutic target in alcohol-related liver disease.
Sarin SK; Pande A; Schnabl B
J Hepatol; 2019 Feb; 70(2):260-272. PubMed ID: 30658727
[TBL] [Abstract][Full Text] [Related]
2. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
Albillos A; de Gottardi A; Rescigno M
J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
[TBL] [Abstract][Full Text] [Related]
3. Alcohol, liver disease and the gut microbiota.
Bajaj JS
Nat Rev Gastroenterol Hepatol; 2019 Apr; 16(4):235-246. PubMed ID: 30643227
[TBL] [Abstract][Full Text] [Related]
4. Alcoholic liver disease: the gut microbiome and liver cross talk.
Hartmann P; Seebauer CT; Schnabl B
Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593
[TBL] [Abstract][Full Text] [Related]
5. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
Ferrere G; Wrzosek L; Cailleux F; Turpin W; Puchois V; Spatz M; Ciocan D; Rainteau D; Humbert L; Hugot C; Gaudin F; Noordine ML; Robert V; Berrebi D; Thomas M; Naveau S; Perlemuter G; Cassard AM
J Hepatol; 2017 Apr; 66(4):806-815. PubMed ID: 27890791
[TBL] [Abstract][Full Text] [Related]
6. Are Probiotics Effective in Targeting Alcoholic Liver Diseases?
Hong M; Han DH; Hong J; Kim DJ; Suk KT
Probiotics Antimicrob Proteins; 2019 Jun; 11(2):335-347. PubMed ID: 29687200
[TBL] [Abstract][Full Text] [Related]
7. Alcohol or Gut Microbiota: Who Is the Guilty?
Meroni M; Longo M; Dongiovanni P
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540133
[TBL] [Abstract][Full Text] [Related]
8. Solid-state fermented Chinese alcoholic beverage (baijiu) and ethanol resulted in distinct metabolic and microbiome responses.
Fang C; Du H; Zheng X; Zhao A; Jia W; Xu Y
FASEB J; 2019 Jun; 33(6):7274-7288. PubMed ID: 30857422
[TBL] [Abstract][Full Text] [Related]
9. Targeting the gut microbiota to treat alcoholic liver diseases: evidence and promises.
Leclercq S; de Timary P; Stärkel P
Acta Gastroenterol Belg; 2020; 83(4):616-621. PubMed ID: 33321019
[TBL] [Abstract][Full Text] [Related]
10. Microbiota-based treatments in alcoholic liver disease.
Sung H; Kim SW; Hong M; Suk KT
World J Gastroenterol; 2016 Aug; 22(29):6673-82. PubMed ID: 27547010
[TBL] [Abstract][Full Text] [Related]
11. Lychee (Litchi chinensis Sonn.) Pulp Phenolic Extract Provides Protection against Alcoholic Liver Injury in Mice by Alleviating Intestinal Microbiota Dysbiosis, Intestinal Barrier Dysfunction, and Liver Inflammation.
Xiao J; Zhang R; Zhou Q; Liu L; Huang F; Deng Y; Ma Y; Wei Z; Tang X; Zhang M
J Agric Food Chem; 2017 Nov; 65(44):9675-9684. PubMed ID: 29041775
[TBL] [Abstract][Full Text] [Related]
12. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
[TBL] [Abstract][Full Text] [Related]
13. The Gastrointestinal Microbiome: Alcohol Effects on the Composition of Intestinal Microbiota.
Engen PA; Green SJ; Voigt RM; Forsyth CB; Keshavarzian A
Alcohol Res; 2015; 37(2):223-36. PubMed ID: 26695747
[TBL] [Abstract][Full Text] [Related]
14. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice.
Chen P; Torralba M; Tan J; Embree M; Zengler K; Stärkel P; van Pijkeren JP; DePew J; Loomba R; Ho SB; Bajaj JS; Mutlu EA; Keshavarzian A; Tsukamoto H; Nelson KE; Fouts DE; Schnabl B
Gastroenterology; 2015 Jan; 148(1):203-214.e16. PubMed ID: 25239591
[TBL] [Abstract][Full Text] [Related]
15. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.
Huang W; Kong D
Biomed Pharmacother; 2021 Mar; 135():111235. PubMed ID: 33561650
[TBL] [Abstract][Full Text] [Related]
16. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans.
Maccioni L; Gao B; Leclercq S; Pirlot B; Horsmans Y; De Timary P; Leclercq I; Fouts D; Schnabl B; Stärkel P
Gut Microbes; 2020 Nov; 12(1):1782157. PubMed ID: 32588725
[TBL] [Abstract][Full Text] [Related]
17. Promises of microbiome-based therapies.
Bajaj JS; Ng SC; Schnabl B
J Hepatol; 2022 Jun; 76(6):1379-1391. PubMed ID: 35589257
[TBL] [Abstract][Full Text] [Related]
18. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease.
Dubinkina VB; Tyakht AV; Odintsova VY; Yarygin KS; Kovarsky BA; Pavlenko AV; Ischenko DS; Popenko AS; Alexeev DG; Taraskina AY; Nasyrova RF; Krupitsky EM; Shalikiani NV; Bakulin IG; Shcherbakov PL; Skorodumova LO; Larin AK; Kostryukova ES; Abdulkhakov RA; Abdulkhakov SR; Malanin SY; Ismagilova RK; Grigoryeva TV; Ilina EN; Govorun VM
Microbiome; 2017 Oct; 5(1):141. PubMed ID: 29041989
[TBL] [Abstract][Full Text] [Related]
19. Integrated Analyses of the Gut Microbiota, Intestinal Permeability, and Serum Metabolome Phenotype in Rats with Alcohol Withdrawal Syndrome.
Yang F; Wei J; Shen M; Ding Y; Lu Y; Ishaq HM; Li D; Yan D; Wang Q; Zhang R
Appl Environ Microbiol; 2021 Aug; 87(18):e0083421. PubMed ID: 34190609
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
